A new study has found that Helicobacter pylori, a microorganism that resides in human abdomen and causes ulcers, redness and abdomen cancers, has gained such a lot resistance to 2 unremarkably used antibiotics — antiprotozoal and levofloxacin that the medication might not be ready to offer any relief to any extent further.
The connection between humans and pathogens are quite dynamic. Whilst human existence depends on an ability to avoid the pathogens, their survival depends on how well they can infect and flourish on humans.
In this constant battle, pathogens keep modifying themselves to counteract the newer and newer medication that humans develop to kill them. Over-use of antibiotics expedites this method resulting in a rise in range of antibiotic-resistant bacterium within the surroundings.
“The study was aimed to gain insights on the prevalence and mechanism of drug resistance in Helicobacter linked diseases so as to help develop strategies with more rational antibiotic combinations for treatment. This will also help implement precise therapy and thus prevent recurrence of the infections,” says Mamatha Ballal, Professor at Kasturba Medical College based at Manipal, Karnataka and leader of the research team.
For their study, researchers collected tissue from 180 patients found positive for helicobacter infection while getting treatment at Kasturba Medical College and tertiary care hospital. The patient dataset comprised of people from nine districts of Karnataka.
They were able to segregate helicobacter strains from 113 patients, which were then tested for their resistance against five routinely used antibiotics.
The results showed that fourteen per cent of strains were immune to all the tested antibiotics and fifty nine.3 per cent of fifty nine.3 per cent of strains were found to be immune to quite one antibiotic: eighty six per cent of this ton were immune to each antiprotozoal drug and levofloxacin.
This means that for all real purposes metronidazole and levofloxacin are no more effective against helicobacter infections in Karnataka.
“This study can act as a strong foundation to progress in national epidemiological surveillance which will be beneficial in evidence-based treatment and also as a managerial follow-up of eradication of Helicobacter if the first line treatment fails,” added Ballal.
The research team included Vignesh Shetty, Ganesh C. Pai, Ramachandra Lingadakai, Girisha Balaraju and Shiran Shetty from Kasturba Medical College and Dr. Eng Guan Chua, Binit Lamichhane and Chin Yen Tay of University of Western Australia. They have published a report on the work in the journal Gut Pathogens